United Therapeutics
UTHR
360 hedge funds and large institutions have $4.6B invested in United Therapeutics in 2018 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 108 increasing their positions, 139 reducing their positions, and 50 closing their positions.
0.41% less ownership
Funds ownership: 98.6% → 98.19% (-0.41%)
2% less funds holding
Funds holding: 367 → 360 (-7)
12% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 50
16% less capital invested
Capital invested by funds: $5.48B → $4.6B (-$883M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
22% less repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 139
32% less call options, than puts
Call options by funds: $6.29M | Put options by funds: $9.31M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$29.3M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$27.6M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$21.7M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$16.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
-$40.9M |
| 2 |
AC
Armistice Capital
New York
|
-$37.3M |
| 3 |
Goldman Sachs
New York
|
-$23M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$16.5M |
| 5 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$15.7M |
UTHR Hedge Fund Activity: Q4 2018 in Review
360 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q4 2018, worth a combined $4.6B — down 16% from $5.48B a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of UTHR and 44 opened new positions — a net loss of 6 holders — while 139 trimmed existing stakes and 108 added.
The largest buyer was Renaissance Technologies, adding an estimated $29.3M. The largest seller was Jupiter Investment Management, exiting entirely with an estimated $40.9M sold.
- 360 institutional investors held United Therapeutics (UTHR) as of Q4 2018, down from 367 in Q3 2018.
- Funds reported $4.6B of United Therapeutics stock for Q4 2018, down 16% quarter-over-quarter.
- 44 funds opened new United Therapeutics positions in Q4 2018 and 50 closed out, a net change of -6 holders.
- The largest United Therapeutics buyer in Q4 2018 was Renaissance Technologies, an estimated $29.3M added.
- The largest United Therapeutics seller in Q4 2018 was Jupiter Investment Management, an estimated $40.9M sold.
Based on aggregated 13F filings for Q4 2018.